Sichuan Kelun Pharmaceutical Co.,Ltd.(002422),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

002422 Sichuan Kelun Pharmaceutical Co.,Ltd.

Closed 12-12 15:00:00

31.15

-0.84

-2.63%

High32.10	Low30.99	Vol25.69M
Open32.00	D1 Closing31.99	Amplitude3.47%
Mkt Cap49.78B	Tradable Cap40.68B	Total Shares1.60B
T/O804.00M	T/O Rate1.97%	Tradable Shares1.31B
P/B2.16	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"002422","market":"SZ","secType":"STK","nameCN":"Sichuan Kelun Pharmaceutical Co.,Ltd.","latestPrice":31.15,"timestamp":1765523034000,"preClose":31.99,"halted":0,"volume":25685510,"delay":0,"changeRate":-0.0263,"floatShares":1306000000,"shares":1598000000,"eps":1.0423,"marketStatus":"Closed","change":-0.84,"latestTime":"12-12 15:00:00","open":32,"high":32.1,"low":30.99,"amount":804000000,"amplitude":0.0347,"askPrice":31.15,"askSize":160,"bidPrice":31.13,"bidSize":166,"shortable":0,"etf":0,"ttmEps":1.0423,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":5,"adr":0,"adjPreClose":31.99,"symbolType":"stock","openAndCloseTimeList":[[1765503000000,1765510200000],[1765515600000,1765522800000]],"highLimit":35.19,"lowLimit":28.79,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1598053372,"isCdr":false,"pbRate":2.16,"roa":"--","peRate":29.885829,"roe":"5.18%","epsLYR":1.86,"committee":-0.032,"marketValue":49779000000,"turnoverRate":0.0197,"status":1,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2025-12-15.","floatMarketCap":40678000000},"requestUrl":"/m/hq/s/002422/wiki","defaultTab":"wiki","newsList":[{"id":"2590391575","title":"Kelun Pharmaceutical's Five Drugs Secure Place on China's Medical Insurance List","url":"https://stock-news.laohu8.com/highlight/detail?id=2590391575","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590391575?lang=en_us&edition=fundamental","pubTime":"2025-12-09 12:16","pubTimestamp":1765253809,"startTime":"0","endTime":"0","summary":"Five of Sichuan Kelun Pharmaceutical's  drugs were included in China's national basic medical insurance catalog, according to a Shenzhen bourse filing on Tuesday.The drugs include meropenem or sodium chloride injection and cetuximab N01 injection.The pharmaceutical company's shares fell less than 2% during the midday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","002422","LU1934453819.USD","LU1979443071.USD","BK0239","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"1103028385","title":"Sichuan Kelun Pharmaceutical (002422.SZ): Five of Its Drugs Included in National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=1103028385","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103028385?lang=en_us&edition=fundamental","pubTime":"2025-12-08 18:14","pubTimestamp":1765188861,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ) announced that, according to the notice jointly issued by the National Healthcare Security Administration and the Ministry of Human Resources and...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1979443071.USD","BK0060","LU1934453819.USD","LU1064130708.USD","LU2148510915.USD","002422","LU1064131003.USD","BK0239"],"gpt_icon":0},{"id":"2588888137","title":"BUZZ-Crescent Biopharma jumps after cancer drug partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2588888137","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588888137?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:24","pubTimestamp":1764851056,"startTime":"0","endTime":"0","summary":"BUZZ-Crescent Biopharma jumps after cancer drug partnership ** Shares of drugmaker Crescent Biopharma CBIO.O rise 36.5% to $18.30 premarket ** Co says it has formed an exclusive partnership with China's Kelun-Biotech to develop and market new cancer treatments** Co is also raising $185 million from investors to fund clinical trials - CBIO** Says deal gives Kelun-Biotech rights to co's experimental drug CR-001 in Greater China** CBIO's CR-001 aims to boost immune response and block blood supply to tumors; SKB105 targets solid tumors, co says** Both firms plan to test drugs alone and in combination; human trials for 3 drugs set for 2026, co says** Up to last close, stock was down ~46% YTD   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL4N3XA0UJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","IVX.AU","LU1934453819.USD","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","06990","BK7096","BK7509","CBIO","002422","BK1161","LU1979443071.USD","BK7508","LU0196878994.USD","BK0239","BK4139"],"gpt_icon":0},{"id":"2588868458","title":"Crescent Biopharma and Kelun-Biotech Launch Strategic Oncology Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2588868458","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588868458?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847814,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc. has announced a strategic partnership with Kelun-Biotech to jointly develop and commercialize novel oncology therapeutics. Under the terms of the collaboration, Crescent has granted Kelun-Biotech exclusive rights to research, develop, manufacture, and commercialize CR-001, a PD-1 x VEGF bispecific antibody, in Greater China, while Crescent has received exclusive rights to develop and commercialize SKB105, an integrin beta-6-directed antibody-drug conjugate , in the United States, Europe, and other markets outside Greater China. The partnership aims to advance both drug candidates as monotherapies and in combination, with both expected to enter Phase 1/2 clinical trials in early 2026. The collaboration is designed to accelerate development and maximize the potential of these therapies for cancer treatment globally.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ti","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL4ZhvgN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IE00B64PRP62.GBP","LU0196878994.USD","LU1979443071.USD","06990","BK4139","BK4585","BK0239","LU2148510915.USD","LU2210150020.SGD","BK4588","LU1934453819.USD","LU2210149790.SGD","BK0060","IE00B3QW5Z07.USD","IE00BKPKM429.USD","NDAQ","BK4112","LU1064130708.USD","002422","LU1064131003.USD","LU0314104364.USD","LU2095319765.USD","IE00BGHQF748.EUR","CBIO"],"gpt_icon":0},{"id":"2588886556","title":"Crescent Biopharma Inc - Kelun-Biotech Eligible for Milestones up to $1.25 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2588886556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588886556?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1064131003.USD","LU0196878994.USD","LU1934453819.USD","BK0060","BK1161","06990","BK0239","LU1979443071.USD","BK4139","LU2148510915.USD","002422","LU1064130708.USD","CBIO"],"gpt_icon":0},{"id":"2588886301","title":"Crescent Biopharma Inc - Co to Receive $20 Mln Upfront Payment,Additional Milestones of up to US$30 Mln From Kelun-Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2588886301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588886301?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CBIO","LU1064130708.USD","LU1934453819.USD","06990","BK0060","BK1161","LU1979443071.USD","BK4139","BK0239","LU0196878994.USD","LU1064131003.USD","002422","LU2148510915.USD"],"gpt_icon":0},{"id":"2588886300","title":"Crescent Biopharma Inc - Kelun-Biotech to Receive $80 Mln Upfront Payment,Additional Milestones of up to US$1.25 Billion From Crescent","url":"https://stock-news.laohu8.com/highlight/detail?id=2588886300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588886300?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06990","BK0239","BK0060","LU1064130708.USD","BK4139","LU1064131003.USD","LU1979443071.USD","LU1934453819.USD","002422","CBIO","LU2148510915.USD","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2588885002","title":"Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2588885002","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588885002?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:30","pubTimestamp":1764847800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA4Q2D7Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2148510915.USD","CBIO","LU1934453819.USD","LU1064131003.USD","LU1979443071.USD","BK0239","06990","002422","BK1161","LU0196878994.USD","BK0060","LU1064130708.USD","BK4139"],"gpt_icon":0},{"id":"2586704672","title":"Kelun-Biotech Reports Promising Phase II Results for Sacituzumab Tirumotecan in Advanced Urothelial Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2586704672","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586704672?lang=en_us&edition=fundamental","pubTime":"2025-11-28 12:07","pubTimestamp":1764302841,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the publication of results from a Phase II clinical study evaluating sacituzumab tirumotecan  monotherapy in patients with advanced or metastatic urothelial carcinoma. The results, already published in the Annals of Oncology, are based on cohort 9 of the MK-2870-001/KL264-01 study and assess sac-TMT in patients whose disease progressed following chemotherapy and immune checkpoint inhibitors. Sac-TMT is a TROP2 antibody-drug conjugate that utilizes an irreversible conjugation technology with a novel topoisomerase I inhibitor payload . As of February 17, 2025, 49 participants were treated with sac-TMT. The confirmed objective response rate was 31%, with a disease control rate of 71% and a median progression-free survival of 5.5 months. The safety profile was considered manageable, with the most frequent grade 3 or 4 adverse events being hematologic toxicities and stomatitis. These results support further evaluation of sac-TM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL3sjPmN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934453819.USD","LU2148510915.USD","LU1064131003.USD","06990","002422","BK0239","LU0196878994.USD","LU1979443071.USD","BK1161","BK0060","LU1064130708.USD"],"gpt_icon":0},{"id":"2585461585","title":"Kelun-Biotech’s Sac-TMT Plus Keytruda Hits Phase III Endpoint in PD-L1-Positive NSCLC Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461585","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585461585?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985636,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that its Phase III clinical trial  evaluating sacituzumab tirumotecan  in combination with KEYTRUDA  as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer  has met its primary endpoint. The Independent Data Monitoring Committee reported a statistically significant and clinically meaningful improvement in progression-free survival , with a positive trend in overall survival also observed. This marks the first Phase III clinical trial of an antibody-drug conjugate combined with an immune checkpoint inhibitor to achieve its primary endpoint in first-line NSCLC treatment. The results have already been concluded as of the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL5cqhCb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002422","BK0060","LU1064131003.USD","LU1934453819.USD","06990","LU0196878994.USD","LU2148510915.USD","LU1064130708.USD","BK1161","LU1979443071.USD","BK0239"],"gpt_icon":0},{"id":"1176614378","title":"Behind an IPO Extortion Case: Pseudo-Media Posing as Journalists and Double-Dealing Financial PR","url":"https://stock-news.laohu8.com/highlight/detail?id=1176614378","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176614378?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:21","pubTimestamp":1763378474,"startTime":"0","endTime":"0","summary":"In September 2023, Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ) reported that false negative articles about the company were circulating online, damaging its commercial reputation. The Xindu...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","002422","LU2148510915.USD","LU1979443071.USD","LU1064130708.USD","LU1064131003.USD","BK0239","LU1934453819.USD"],"gpt_icon":0},{"id":"2584643293","title":"Kelun Pharmaceutical Gets Nod for Registration of Paliperidone Palmitate Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2584643293","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584643293?lang=en_us&edition=fundamental","pubTime":"2025-11-17 16:57","pubTimestamp":1763369834,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical  obtained the approval of China's National Medical Products Administration for the registration of paliperidone palmitate injection, according to a Shenzhen bourse filing on Saturday.The Chinese pharmaceutical company's shares dropped less than 4% at the close of Monday's trade.The company's subsidiary, Hunan Kelun Pharmaceutical, developed and manufactured the oral antipsychotic, which is used to treat schizophrenia.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1979443071.USD","LU1064131003.USD","BK0239","LU2148510915.USD","LU1064130708.USD","BK0060","002422","LU1934453819.USD"],"gpt_icon":0},{"id":"2583559851","title":"Sichuan Kelun Pharmaceutical Gets Registration Approval for 4-Billion-Yuan Bond Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2583559851","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583559851?lang=en_us&edition=fundamental","pubTime":"2025-11-13 15:28","pubTimestamp":1763018934,"startTime":"0","endTime":"0","summary":"China's National Association of Financial Market Institutional Investors accepted Sichuan Kelun Pharmaceutical's  registration of its 4-billion-yuan bond issuance on Wednesday, according to a Thursday filing with the Shenzhen bourse.The registration is valid for two years.China CITIC Bank  is the lead underwriter for the ultra-short-term bonds.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1560","LU1979443071.USD","LU0210526637.USD","US2Y.BOND","LU1634259557.SGD","US6M.BOND","BK0278","BK0028","TMF","LU0051755006.USD","LU1064130708.USD","BK0183","LU1497733557.USD","00998","601998","BK1231","LU1634259391.SGD","002422","BK0187","LU0572939691.SGD","US3Y.BOND","US30Y.BOND","LU1064131003.USD","BK0188","LU1497733631.SGD","BK0012","LU2148510915.USD","LU1522347837.USD","US10Y.BOND","US7Y.BOND","TLTW","BK0239","BK0060","LU0456827905.SGD","LU1497734951.SGD","LU0264606111.USD","LU1934453819.USD","US5Y.BOND","LU0572940350.SGD","US12M.BOND","BK0201","BK0015"],"gpt_icon":0},{"id":"2582810815","title":"Kelun-Biotech Reports Positive Phase II Results for Sacituzumab Tirumotecan in NSCLC at CCHIO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2582810815","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582810815?lang=en_us&edition=fundamental","pubTime":"2025-11-10 10:09","pubTimestamp":1762740555,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has presented new clinical study results for its TROP2 antibody-drug conjugate , sacituzumab tirumotecan , at the 2025 Chinese Congress on Holistic Integrative Oncology , held in Kunming, Yunnan from November 6 to 9, 2025. The company reported preliminary data from a Phase II trial evaluating sac-TMT in patients with locally advanced or metastatic non-small cell lung cancer  harboring uncommon EGFR mutations. Among 42 patients, the objective response rate  was 35.7%, with a disease control rate  of 85.7% and a median progression-free survival  of 9.5 months. Additionally, results from a non-squamous NSCLC cohort in a Phase II study combining sac-TMT with tagitanlimab  as first-line therapy were presented. Among 81 patients, the confirmed ORR was 59.3%, DCR was 91.4%, and median progression-free survival reached 15.0 months. No treatment-related adverse events led to discontinuation or death. These results were presented as oral presenta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL1h5thP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU1934453819.USD","BK0060","LU1064130708.USD","06990","LU2148510915.USD","002422","LU1064131003.USD","LU1979443071.USD","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2582101208","title":"Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2582101208","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582101208?lang=en_us&edition=fundamental","pubTime":"2025-11-10 10:01","pubTimestamp":1762740060,"startTime":"0","endTime":"0","summary":"CHENGDU, China, Nov. 10, 2025 /PRNewswire/ -- From November 6 to 9, the 2025 Chinese Congress on Holistic Integrative Oncology  was held in Kunming, Yunnan. This conference was jointly organized by the Chinese Anti-Cancer Association , the Tengchong Science Forum Organizing Committee Office, the World Association for Integrative Oncology , and the China Institute for Integrative Medicine Development Strategy. Academicians, experts, and scholars from across the nation gathered to focus on innovations in cancer diagnosis and treatment while sharing scientific breakthroughs. At the conference, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  presented results from multiple clinical studies on its TROP2 ADC sacituzumab tirumotecan as oral presentations.On November 8, Professor Fang Wenfeng from the Cancer Center of Sun Yat-sen University delivered an oral presentation at the conference on preliminary results from a Phase II study evaluating sac-TMT in treating locally advanced or metasta","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-presented-trop2-adc-sacituzumab-tirumotecan-results-from-multiple-clinical-studies-at-the-2025-cchio-congress-302609625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509010.AUD","002422","BK4007","PFS","LU1066053197.SGD","LU0106261612.USD","LU0238689110.USD","LU1699723380.USD","LU2361044949.HKD","LU2023250504.SGD","LU2023250843.SGD","SG9999015341.SGD","DAR","LU1941712348.USD","LU0265550946.USD","LU1934455277.USD","EC","LU1989772923.USD","LU2361044865.SGD","IE00BSNM7G36.USD","LU1037948541.HKD","LU1934455194.USD","ORR","LU1917777945.USD","LU1162221912.USD","BK4189","BC","MRK","SG9999013999.USD","LU2461242641.AUD","LU2468319806.SGD","SG9999014542.SGD","LU1721429402.USD","LU1291159041.SGD","BK4533","LU2148510915.USD","IE00BFTCPJ56.SGD","ORR.AU","SG9999014567.USD","PR","ADC","MSD","BK4588","LU0234572021.USD","BK4534","LU1093756325.SGD","LU1989772840.SGD","LU0203347892.USD","LU1934453819.USD"],"gpt_icon":0},{"id":"1112256769","title":"Sichuan Kelun Pharmaceutical Increases Stake in SSY GROUP (02005) by 1.128 Million Shares at HK$3.1 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1112256769","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112256769?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:24","pubTimestamp":1762255460,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on October 31, Sichuan Kelun Pharmaceutical Co., Ltd. increased its stake in SSY GROUP (02005) by purchasing 1.128 million shares at...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005","LU2460026573.USD","LU1979443071.USD","BK0239","BK0060","BK1191","LU1064131003.USD","002422","LU1064130708.USD","LU1934453819.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2579432420","title":"Sichuan Kelun Pharmaceutical's Attributable Profit Slides 70% in Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2579432420","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579432420?lang=en_us&edition=fundamental","pubTime":"2025-10-31 15:18","pubTimestamp":1761895105,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical's  attributable profit plunged 70% year over year to 200 million yuan in the third quarter, according to a Friday filing with the Shenzhen bourse.The drug company logged earnings per share of 0.12 yuan, down 71% from the year-ago period.Operating income declined 15% year on year to 4.19 billion yuan.Shares closed 2% higher on Friday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["002422","BK0239","LU1979443071.USD","LU1064130708.USD","LU1934453819.USD","BK0060","LU2148510915.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2576834179","title":"The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2576834179","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576834179?lang=en_us&edition=fundamental","pubTime":"2025-10-20 17:06","pubTimestamp":1760951160,"startTime":"0","endTime":"0","summary":"After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group .OS was significantly longer with sac-TMT than with chemotherapy ; 18-month OS rate was 65.8% and 48.0%, respectively. In the supplementary analysis, in which data were censored at the start date of subsequent ADC, the HR was 0.56 .Sac-TMT was associated with a higher incidence of stomatitis with most cases being mild and with grade 3 or higher cases reported in very few patients . Low incidence of ocular-surface toxic effects, no ILD or pneumonitis, and one infusion-related reaction  was reported in the sac-TMT group.Based on the positive results of the OptiTROP-Lung04 study, sac-TMT has been approved by the National Medical Products Administration  in China for the treatment of adult patie","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/the-new-england-journal-of-medicine-publishes-results-of-phase-iii-optitrop-lung04-study-of-sacituzumab-tirumotecan-in-advanced-egfr-tki-resistant-nsclc-302588860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0265550359.USD","BC","LU1069347547.HKD","SG9999002224.SGD","LU1941712264.USD","CI","LU1023059063.AUD","LU1093756325.SGD","002422","ADC.AU","LU1064130708.USD","LU1941712348.USD","LU0203347892.USD","LU0861579265.USD","LU1291159041.SGD","DAR","BK4203","LU2308191902.HKD","MRK","SG9999014542.SGD","LU0320765489.SGD","LU0965509101.SGD","LU1979443071.USD","LU1934453819.USD","BK4134","BK4534","LU1059921491.USD","OS","III","LU1116320737.USD","BK4559","HR","LU2461242641.AUD","ADC","IE00B4R5TH58.HKD","BK0239","BK4097","LU2324357040.USD","LU1037948897.HKD","MSD","PFS","BK4007","BK4080","LU0965508806.USD","LU0106261612.USD","LU1162221912.USD","IE000M9KFDE8.USD","LU2380233275.USD","LU1699723380.USD"],"gpt_icon":0},{"id":"2576788730","title":"Kelun Pharma Gets Nod for Rotigotine Patch's Registration; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576788730","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576788730?lang=en_us&edition=fundamental","pubTime":"2025-10-20 13:28","pubTimestamp":1760938108,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical  received approval from the Chinese drug administration for the registration of its rotigotine patch, according to a Saturday disclosure on the Shenzhen bourse.The Chinese pharmaceutical company's shares jumped less than 4% during Monday's afternoon trade.The patch, which was first developed by UCB Pharma, is used for the treatment of Parkinson's disease.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1064130708.USD","LU1979443071.USD","BK0060","002422","LU2148510915.USD","LU1064131003.USD","BK0239","LU1934453819.USD"],"gpt_icon":0},{"id":"2576004457","title":"Sichuan Kelun-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2576004457","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576004457?lang=en_us&edition=fundamental","pubTime":"2025-10-20 07:32","pubTimestamp":1760916746,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the presentation of results from multiple clinical studies at the 2025 European Society for Medical Oncology  Congress, held in Berlin, Germany from October 17 to 21, 2025. The studies included data on sacituzumab tirumotecan , a TROP2-directed antibody-drug conjugate , trastuzumab botidotin , a HER2-directed ADC, and SKB315, a Claudin18.2 ADC. Two studies of sac-TMT were selected for Late Breaking Abstract oral presentation, including a Phase 3 study in EGFR-mutated non-small cell lung cancer following progression on EGFR-tyrosine kinase inhibitors. The company also reported ongoing research on SKB315 in combination with immunotherapy and as monotherapy in tumors expressing Claudin18.2. The company cautioned that these drugs are not yet approved for all indications and may not ultimately be successfully developed or commercialized.Disclaimer: This news brief was created by Public Technologies  using generative artificial inte","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251019:nNDL7FfVX3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002422","LU2148510915.USD","BK0060","LU1064131003.USD","LU1934453819.USD","LU1064130708.USD","LU1979443071.USD","06990","BK0239","BK1161","LU0196878994.USD"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-06-03","address":"四川省成都市新都区新都卫星城工业开发区南二路","stockEarnings":[{"period":"1week","weight":-0.0765},{"period":"1month","weight":-0.0598},{"period":"3month","weight":-0.1613},{"period":"6month","weight":-0.1501},{"period":"1year","weight":-0.02},{"period":"ytd","weight":0.0579}],"companyName":"四川科伦药业股份有限公司","boardCode":"AI0027","perCapita":"35201股","boardName":"医药制造业","registeredCapital":"159805万元","compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"survey":"　　四川科伦药业股份有限公司的主营业务是大容量注射剂（输液）、小容量注射剂（水针）、注射用无菌粉针（含分装粉针及冻干粉针）、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等24种剂型药品及抗生素中间体、原料药、医药包材等产品的研发、生产和销售。公司的主要产品是输液、非输液、研发项目、其他。","serverTime":1765725575583,"listedPrice":83.36,"stockholders":"37098人(较上一季度增加8.35%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sichuan Kelun Pharmaceutical Co.,Ltd.(002422),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sichuan Kelun Pharmaceutical Co.,Ltd.(002422) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sichuan Kelun Pharmaceutical Co.,Ltd.,002422,Sichuan Kelun Pharmaceutical Co.,Ltd.股票,Sichuan Kelun Pharmaceutical Co.,Ltd.股票老虎,Sichuan Kelun Pharmaceutical Co.,Ltd.股票老虎国际,Sichuan Kelun Pharmaceutical Co.,Ltd.行情,Sichuan Kelun Pharmaceutical Co.,Ltd.股票行情,Sichuan Kelun Pharmaceutical Co.,Ltd.股价,Sichuan Kelun Pharmaceutical Co.,Ltd.股市,Sichuan Kelun Pharmaceutical Co.,Ltd.股票价格,Sichuan Kelun Pharmaceutical Co.,Ltd.股票交易,Sichuan Kelun Pharmaceutical Co.,Ltd.股票购买,Sichuan Kelun Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sichuan Kelun Pharmaceutical Co.,Ltd.(002422),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sichuan Kelun Pharmaceutical Co.,Ltd.(002422) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction